SOPHiA GENETICS (SOPH) to Release Quarterly Earnings on Tuesday

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) is projected to post its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $16.76 million for the quarter. SOPHiA GENETICS has set its FY 2025 guidance at EPS.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.23) earnings per share for the quarter, meeting the consensus estimate of ($0.23). The firm had revenue of $17.73 million for the quarter, compared to analysts' expectations of $17.71 million. SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. On average, analysts expect SOPHiA GENETICS to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

SOPHiA GENETICS Stock Performance

SOPHiA GENETICS stock traded up $0.01 during mid-day trading on Friday, reaching $3.03. 30,884 shares of the stock traded hands, compared to its average volume of 65,160. SOPHiA GENETICS has a 12-month low of $2.58 and a 12-month high of $6.28. The business's 50-day moving average is $3.10 and its 200-day moving average is $3.36. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.80 and a quick ratio of 3.59. The stock has a market capitalization of $202.06 million, a PE ratio of -2.78 and a beta of 1.02.

Wall Street Analysts Forecast Growth

Separately, BTIG Research set a $5.00 price objective on shares of SOPHiA GENETICS in a report on Thursday, March 6th.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.